TY - JOUR T1 - Quality of life and symptoms improvement after 6 months treatment with roflumilast 500 μg daily in a large Greek COPD cohort JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P2385 AU - Nikolaos Tzanakis AU - Alexandros Ginis AU - Grigoris Politis AU - Grigoris Kaltsas AU - Artemis Nomikou AU - Nikolaos Spandideas AU - Nikolaos M. Siafakas Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P2385.abstract N2 - Background and aimsWe evaluated the changes in MRC dyspnea index and CCQ questionnaire in Greek COPD patients treated with Roflumilast during a 6 month cohort study (ATLAS study).Materials and MethodsChanges in CCQ questionnaire and MRC dyspnea score were evaluated in 2167 patients with severe chronic obstructive pulmonary disease (COPD), FEV1 (% pred) 49.1± 14.7 aged 70.5 ± 9.7 with a mean Body Mass Index of 29.1±4.8 (mean values) following treatment with Roflumilast for a six month observational period. Data were collected at baseline (V0), 3rd (V1) and 6th month (V2). Spirometric evaluation, (FEV1, FVC, FEV/FVC) and body weight measurement were also included.ResultsTotal CCQ questionnaire demonstrated clinically relevant and statistically significant improvement between pre and 6-months post-treatment period (x±SD) Δ=-1.53±1.07, p<0.0001. This improvement was also valid for all three domains, Symptoms, Functional and Mental domain (Δ) (x±SD), -1.56±1.07, 1.58±1.28 and 1.84±1.33, respectively. Overall, patients improved their MRC dyspnea index significantly (Δ, x±SD 1.39± 1.01 p<0.0001) from V0 to V2.Statistically significant changes were also noticed in the number of patients that improved their MRC scores between baseline (V0) and after 6 months (V2) by changing their dyspnea stage (p<0.0001). Conclusion: Six-months treatment with roflumilast 500 μg daily of naive to roflumilast large COPD cohort, showed significant and clinically meaningful early improvement in their MRC dyspnea index and their quality of life. ER -